Dec. 5 at 2:27 PM
$CLSD
Review of milestones, royalty rates, and status:
Bausch: 55 million in milestones, 17-20% royalties, approved
Arctic/Santen: 20 million in milestones, 10-12% royalties, filed in China(main market)
Regenxbio: ~30 million in dev milestones, ~100 milliin in commercial, ~5% royalties, phase 2b/3
Aura: ~20 million in dev milestones, 3-5% royalties, phase 3
Biocryst: ~30 million dev milestones, ~48 million in commercial milestones, 5-7% royalties, phase 1
Total dev milestone floating: ~90 million, total commercial ~215 million.
That is against 106.5 million in obligations to the royalty sub. One thing to take into account when valuing this is that the 106.5 million has to be discounted in the same way as the potential cashflows are.